BrainMap

Mr. Alexandru-Flaviu Tabaran

Professor, Habil, PhD, MSci, Dipl ACVP

Professor - UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Other affiliations

Adjunct Professor - UNIVERSITY OF WYOMING (United States of America)

Researcher - UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (Romania)

Dr. Flaviu Tăbăran (Ph.D., DVM, Habil., Dipl. ACVP) (Brain map ID: U-1700-038Y-4867) currently holds a Professor position at the Faculty of Veterinary Medicine from Cluj-Napoca and Adjunct Professor at the University of Wyoming. He is an ACVP board-certified specialist in veterinary pathology. Between 2017 and 2019: Postdoctoral research pathologist at the University of Minnesota (USA), carrying mainly experimental pathology and toxicology research. Expertise: Veterinary pathology, including experimental pathology; biodistribution and toxicokinetics of particles (vesicles and nanoparticles); classical and special microscopic procedures, including confocal laser scanning microscopy. Publication Record: ●161 peer-reviewed scientific publications [20 first author, 5 –last author, 2-corresponding author, and 118- as co-author], among which 81 scientific articles in extenso published in Thomson Reuters-ISI Indexed Journals.

Web of Science ResearcherID: D-8562-2011

Curriculum Vitae (04/05/2024)

Expertise & keywords

Development of LASER active bio-nanosystems for selective mitochondrial therapy of pancreatic cancer. Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2021-0073 2022 - 2024

Role in this project:

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation:

Project website: https://6387c31887385.site123.me/

Abstract:

Pancreatic cancer is the most lethal tumor of all solid tumors, with a median survival of 6 months from the time of diagnosis, largely due its chemoresistance, a major obstacle in the treatment for this disease. Gemcitabine, standard chemotherapy in the treatment for pancreatic cancer has only a 6.3% response rate and increases overall survival interval with 0.9 to 5.6 months. The aim of the project is to obtain a double therapeutic effect in pancreatic cancer- laser‐mediated nano‐photo‐thermolysis and selective targeted cytotoxicity given by the attached chemotherapeutic agent.

Iron oxide nanoparticles transported by probiotics - cytotoxicity, bioavailability and their influence on intestinal microflora Call name: P 4 - Proiecte de Cercetare Exploratorie, 2020
PN-III-P4-ID-PCE-2020-2126 2021 - 2023

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation:

Project website: https://pronanoiron.usamvcluj.ro/

Abstract:

Anemia is a global issue affecting 2 billion people. Over 52% of pregnant women suffer from anemia. Scientists' bigger concern is iron bioavailability and gastrointestinal side effects. A promising approach for anemia treatment is the utilization of iron oxide nanoparticles. We will empower the iron oxide nanoparticles with probiotics from Lactobacillus and Bifidobacterium species, leading to a reduction of gastrointestinal discomfort, an increase in iron absorption and reduced problems pose of toxicity.

Our overall objective is to design, develop and test an innovative probiotic (Lactobacillus and Bifidobacteria) carrier iron oxide nanoparticles suitable for i) anemia treatment with ii) minimum side effects (no cytotoxicity) that sustain iii) optimum iron absorption mechanism and iv) ensure the gut microbiota health, in order to maximize their impact. Specific objectives will be achieved through seven work packages (WP1-7):

WP1-Synthesis and characterization

WP2-Functionalization

WP3 -In vitro simulated gastrointestinal interventions

WP4-In vitro cellular uptake and cytotoxicity

WP5-In vivo validation of the anemia treatment using probiotic iron oxide nanoparticles

WP6-Scientific and social innovation, dissemination, communication & exploitation

WP7-Management

The potential impact on budgets for health care is considerable; considering that over 30% of the population is anemic, many due to iron deficiency. The research will encourage an interdisciplinary approach.

Selective Nano-mediated Modal Therapies for Digestive Oncological Pathology Applications. Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-0997 2020 - 2022

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Project website: https://drteodoramocan.wixsite.com/nanopod/obiectiv-general

Abstract:

Hepatocarcinoma (HC) represents the fourth leading cause of cancer death worldwide, having an overall 5-year survival rate of less than 5%. At the current time, the surgical resection of the primary tumor is the only therapeutically approach that provides improvement in survival. The project aims to produce nano-agents including a chemotherapy agent (5-FU) that will be released upon gene silencing to avoid therapy evasion and to provide dual mode real time imaging. The project could provide clinicians with an additional tool to improve management of digestive pathologies.

Theranostic microplatforms for multimodal therapy in human eye diseases, a new paradigm for the biomedical applications Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-4558 2020 - 2022

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO); UNIVERSITATEA BABES BOLYAI (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: https://sites.google.com/usamvcluj.ro/microplatthera

Abstract:

The diabetic retinopathy affects the vision of people all over the world, leding to definitive blindness. In an effort to decrease the incidence of diabetic retinopathy, medical representatives and institutions are being driven to develop new strategies to improve the commonly used therapies. The current proposal is challenging and aims to push the knowledge beyond the state of the art by improving a pre-existent microsystem with attested anti-VEGF potential and transforming it into theranostic microplatforms (TPs) for multi-modal diabetic retinopathy therapy. To evaluate the biological effects of the theranostic microplatforms, two types of human cellular eye models exposed to simulated diabetic retinopathy conditions will be used. This research seeks to take use of the novel technology to develop and validate the theranostic microplatforms targeted to the VEGF protein from human retina cells and enable them to release the carried therapeutic molecules localized by using one non-invasive external irradiation source.

Innovative materials as dietary suppliments for healthcare Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-3373 2020 - 2022

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA BABES BOLYAI

Project partners: UNIVERSITATEA BABES BOLYAI (RO); INSTITUTUL NATIONAL DE CERCETARE DEZVOLTARE PENTRU OPTOELECTRONICA INOE 2000 INCD FILIALA INSTITUTUL DE CERCETARI PENTRU INSTRUMENTATIE ANALITICA CLUJ NAPOCA (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://www.chem.ubbcluj.ro/romana/ANEX/cf/pcas/IMA_Health/index_IMA_Helath.htm

Abstract:

IMA-HEALTH project aims to validate at laboratory scale (TRL4), preparation methods (2) of poorly crystallized (HAP1) and highly crystallized (HAP2), sub-micron pure HAP and multi-substituted HAP (ms-HAP) with essential elements for bone regeneration. IMA-HEALTH project aims to validate at TRL4, the complex of HAP and ms-HAP with D3 and K2 vitamins, resulting (8) IMA-HEALTH dietary supplements to support the proper deposition of calcium into bone matrix, thereby maintaining skeletal integrity, and cardiovascular and arterial health. These supplements are expected to have a high effect on osteoblasts and endothelial cells related to the production of alkaline phosphatase, which is essential in regeneration of healthy new bone with impact on prevention and treatment of osteoporosis, and cardiovascular and arterial health. IMA-HEALTH is based on existing preparation methods for obtaining nano HAP with controlled size and shape of particles and crystallinity, at TRL2, previous research projects and Romanian patent. Main objective: •validation at lab scale of preparation methods/advanced materials based on sub-micron HAP as dietary supplements for healthcare. Specific objectives: •increasing the capacity of research organizations to develop innovative solutions validated in lab; •review of existing technical documentation; •development of sub-micron size HAP and hydroxyapatite/vitamins complexes; •optimization of IMA-HEALTH advanced materials EM; •demonstrating the utility and functionality of IMA-HEALTH, EM (TRL3); •validation of IMA-HEALTH, EM at lab scale (TRL4); •dissemination. Project end-products: validation at lab scale TRL4 of 2 preparation methods for HAP1 and HAP2, and 8 IMA-HEALTH dietary supplements: HAP, HAP/D3, HAP/K2, HAP/D3/K2, and ms-HAP, ms-HAP/D3, ms-HAP/K2, ms-HAP/D3/K2 poorly and highly crystallized - designed to replace imported dietary supplements at lower costs and in consequence, capable to compete on EU market, helping Romanian SMEs and economy.

Fluorescent pH-sensitive nano-sized systems for intracellular melanoma monitoring Call name: P 1 - SP 1.1 - Proiecte de cercetare pentru stimularea tinerelor echipe independente
PN-III-P1-1.1-TE-2019-1276 2020 - 2022

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: https://sites.google.com/usamvcluj.ro/nanoansys

Abstract:

The World Health Organization warns that the incidence of skin cancers has been increased over the past decades. This warning forced the scientists to develop new strategies for melanoma therapy. In this context, our goal is to obtain pH-sensitive nanosystems to carry anthocyanins (AnSys) directly into melanoma cells, where their delivery, subcellular localization and their pH-controlled release will be monitored. For this purpose the main objectives are: (i) to design and develop the smart fluorescent pH-sensitive nanosystem as carrier for anthocyanins; (ii) to evaluate the efficient release of the entrapped anthocyanins under specific pH conditions, by liquid cromatography coupled with mass spectrometry; (iii) to monitor the pH-dependent intracellular processes after the AnSys internalization into melanoma cells, by using non-invasive high-performance fluorescence microscopy techniques. Therefore, the current proposal is highly scored in novelty-seeking, because there is no data available on a similar pH responsive nanocarrier system, able to facilitate the controlled release of anthocyanins in melanoma tumor cells.

Nanovaccinal Approaches for Colon Cancer Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-0844 2020 - 2022

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO); INSTITUTUL NATIONAL DE CERCETARE DEZVOLTARE PENTRU OPTOELECTRONICA INOE 2000 INCD FILIALA INSTITUTUL DE CERCETARI PENTRU INSTRUMENTATIE ANALITICA CLUJ NAPOCA (RO); UNIVERSITATEA TEHNICA DIN CLUJ - NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: https://nanovacol.wixsite.com/homero?lang=en

Abstract:

Colon cancer is a major cause of deaths worldwide, and it is expected to rise in the coming years. The development of nanoscale delivery of active substances represents an exciting and new approach to cancer immunoprophylaxis. General aim of the project would be to conjugate an immunogenic antigen to gold nanoparticles in order to promote major histocompatibility complex- involving antigen processing by antigen presenting cells. Tailored pharmaceutical formulation of by a specially designed capsule is going to be used, in order to offer optimal intestinal delivery of nano-bio celular vaccine.

Mannan-Coated Gold-Silver Alloy Nanoparticles for Delivery to Immune Cells: New Approaches to Targeted Therapy for Tuberculosis Call name:
PN-III-P1-1.1-PD-2016-1840 2018 - 2020

Role in this project: Project coordinator

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/projects.html#BiNano-Myc

Abstract:

Emergence of multidrug-resistance represents the main cause of the current status of Tuberculosis (TB) as a major global health problem. The most intriguing property of Mycobacteria which is considered the main obstacle in formulating a rational design of antimycobacterial drug is represented by the capacity of such bacteria to survive and multiply inside the macrophages, this "phagocyte-sabotage" ensuring not only the avoidance of both innate and acquired immune system, but also provide a way of systemic dissemination, a cause of clinical relapse and selection of aggressive strains with antibiotic resistance. We propose to develop a gold-silver alloy based bio-nanostructure (Au-AgNP) designed by functionalization with the polysaccharide-mannan for intra-macrophage targeted therapy of Mycobacterium tuberculosis complex (MtbC) infections. Employing the selective recognition of the mannan by the mannose receptor, primarily expressed on the surface of macrophage-family cells, we hypothesize that the Mannan-coated Au-Ag construct will improve the local availability of nanoparticle and enhance the mycobactericidal effect of AgNP and AuNP, nanoparticles which already show promising results in tuberculosis therapy. To assure the best report between antimycobacterial efficiency and the cytotoxic activity, ascending molar concentration of Au in the molecule and increasing doses of Au-AgNP, will be tested on M. tuberculosis cultures and in Mtb infected macrophages.

Mannan-Coated Gold-Silver Alloy Nanoparticles for Delivery to Immune Cells: New Approaches to Targeted Therapy for Tuberculosis Call name: P 1 - SP 1.1 - Proiecte de cercetare Postdoctorală
PN-III-P1-1.1-PD-2016-1840 2018 - 2020

Role in this project: Project coordinator

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: https://binanomyc.wixsite.com/pn3-research-grant

Abstract:

Multi-modal targeted nano-mediated therapy of liver cancer. Call name: P 1 - SP 1.1 - Proiecte de cercetare pentru stimularea tinerelor echipe independente
PN-III-P1-1.1-TE-2016-2161 2018 - 2020

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Project website: http://nmn.ro/projects.html#NANOMULTIHCC

Abstract:

The general goal of this project is to develop a novel therapy tool for hepatocellular carcinoma (HCC) based on a multi-modal treatment strategy . The strategy involves the deveopment of a therapeutic system that acts synergically as thermal inducer agent and chemotherapeutics. We will test the product using in vitro, in vivo and ex vivo biological platforms.

Smart polyelectrolyte multilayer capsules for controlled release of bioactive compounds Call name: P 1 - SP 1.1 - Proiecte de cercetare pentru stimularea tinerelor echipe independente
PN-III-P1-1.1-TE-2016-1907 2018 - 2020

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: https://www.smartpems.com/

Abstract:

Unceasing efforts are currently made by researchers worldwide to improve drug delivery systems. Despite the nanobiotechnology advances in functionalising nano- and micro-particles particles for delivery agents and contrast therapies, there is still a great need for nanoparticles and microparticles that can specifically bind, stabilise and deliver therapeutic agents inside human cells and tissues. Here we propose desiging an optically addresable, controlled release delivery system with low based on polyelectrolyte multilayer capsules. The system should facilitate controlled, targeted release of the cargo upon exposure to laser light and. The multifunctional system is based on carotenoids and gold nanoparticles encapsulated in a polyelectrolyte multilayer matrix. A laser mediated procedure will be used to facilitate the carotenoid content release. Carotenoids will be used as model system for the bioactive compound. The gold nanoparticles are used in connection to their plasmonic properties. Under laser irradiation they are expected to transform light into heat and to facilitate the release of the carotenoids. Such a controlled release system would have the clear advantages of improving the delivery of bioactive compounds, with great potential of applications in the field of nanomedicine.

Signaling pathways and target molecules involved in chemoprevention with nanosilver – natural extract conjugates in oral carcinogenesis Call name: P 4 - Proiecte de Cercetare Exploratorie
PN-III-P4-ID-PCE-2016-0396 2017 - 2019

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Project website: http://www.granturi.umfcluj.ro/ORNANOCHEM/

Abstract:

Oral squamous cell carcinoma represents a major global health problem due to its high incidence (2% - 3% of all malignancies), association with 5-year survival rate below 50% and a relatively high risk of relapse. Risk factors can induce DNA damage and alter the expression of various gene products implicated in defensive or reparative processes such as apoptosis, genomic repair and cell growth arrest directly or by reactive oxygen species. Consequently, it can drive genomic instability, disruption of cell signaling pathways, events that can lead to neoplastic transformation and ultimately carcinogenesis. Accordingly, development of early detection and preventive strategies is essential.

In our study we aim to evaluate in vitro and in vivo effects of silver nanoparticles functionalized with natural extracts derived from Sambucus nigra (SN) and Cornus mas (CM). In order to validate the nanochemopreventive potential of new hybrid biomaterials we estimate the effect on oral dysplastic keratinocytes and oral chemically-induced carcinogenesis in Sprague-Dawley rats by evaluating the gene expression profile (p53, WNT and PI3K-AKT signaling pathways), metabolic and epigenetic mechanisms, using cDNA microarray technology and real-time polymerase chain reaction (PCR-RT). In vitro and in vivo validation of qRT-PCR data are performed by evaluation of protein expression profile using western blot. Also, by histopathological examinations we identify key molecules and signaling pathways involved in chemoprevention. In order to detect cancer cell through their mechanical properties we use atomic force microscopy.

The project put forward, using cutting edge research, brings new scientific insight regarding protection at a molecular level using hibrid materials prepared from silver nanoparticles and natural products, and offers scientific viable solutions for nanochemoprevention.

The development of a control released drug system for the prevention of intestinal fungal complications in patients with chronic antibiotic treatment Call name: P 2 - SP 2.1 - Transfer de cunoaștere la agentul economic „Bridge Grant”
PN-III-P2-2.1-BG-2016-0446 2016 - 2018

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO); ORGANIC PLANT AGE SRL (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/projects.html#Slam

Abstract:

Similar to immunosuppressive treatment, the antibiotic treatment represents one of the major factors for fungi complications, through alteration of bacterial colonization, immunosupresive effect and by means of creating the perfect local conditions for fungal overgrowth. Oral antibiotic treatment represents one of the major therapeutic type of administration for both local and systemic infections, for both hospitalized and non-hospitalized patients. Fungal overgrowth with various localizations: urogenital, oral cavity, systemic, intestinal (e.g. Candida – Candida albicans) represents an unwanted effect, with severe consequences of antibiotic .Present project proposed the construction of an unique pharmaceutic system that would combine the effects of an active antibiotic effect with the effects of an antifungal protective substance. Synthesis technologies will be carried out for the purpose of generating various types of pharmaceutic formulations, along with testing and selection of optimal solution. Expertise transfer towards The Company will include the newly designed prototype, results of synthesis, characterization and testing techniques. Also, adapted solutions for technological adjustments needed for production of new compound will be delivered.

Development of some functional nutraceutical products with applications in healthy nutrition and regenerative medicine, obtained by using an innovative and sustainable technology. Call name: P 2 - SP 2.1 - Transfer de cunoaștere la agentul economic „Bridge Grant”
PN-III-P2-2.1-BG-2016-0335 2016 - 2018

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO); UNIVERSITATEA BABES BOLYAI (RO); EMBRYOM CAPITAL INVESTMENT SRL (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: http://www.usamvcluj.ro/profi-zonar/

Abstract:

The objective of the PROFI-ZONAR project consists in the development of an innovative and functional nutraceutical products based on Zonar (lactoser or whey), with practical applications in preventive & regenerative medicine. The main objectives of the project concern: 1) physico-chemical characterization of the Zonar obtained by using an innovative and sustainable technology developed by SC.EmbryOm Capital Investment SRL; 2) determination of biological properties (functional & nutraceuticaL) of diets based on Zonar in animals with diabetes mellitus, Walker 256 carcinoma ; 3) using in vitro models for studyi biological effects of bioactive compounds from Zonar; 4) obtaining polylactic polymers from Zonar, using an innovative technology and testing their regenerative effect on bone lesions. To achieve these objectives, there will be used modern methods for characterization the bioactive components from Zonar, as well as the physico-chemical properties of the final products. The study of biological effects of Zonar & of polylactic polymers will be carried out in vivo models (diabetes mellitus, Ehrlich ascite in mice, Walker 256 carcinoma in rats, bone regeneration after traumatic lesson) and in vitro, using cell culture of fibroblasts & tumor cell line (HeLa). The research outcomes will contribute to clarifying the biochemical composition and the biological effects of Zonar, as functional nutraceutical product, as well as to developing a patent in order to implement Zonar on national and international market. The innovative impact of the research is given by the development of the polylactic polymers through a competitive and sustainable technology, using Zonar as affordable and economically advantageous source. Patenting the technological process of synthesis of polylactic polymers from Zonar represent also an important goal of the research, contributing in this way to the widespread use of the Zonar on the national and international nutrition and biomedical markets.

Co-transplantation of human derived immune stimulatory macrophages and mezenchymal stem cells for optic nerve regeneration in a glaucoma animal model Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2016-1490 2017 - 2018

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO); INSTITUTUL ONCOLOGIC PROF.DR.I.CHIRICUTA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO)

Project website: http://www.crma.ro/glaucostem/index.php

Abstract:

The development of a gold based bio-nanostructure for treatment of Klebsiella Pneumoniae infections via nano-photothermolysis Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2016-1742 2017 - 2018

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU" (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/projects.html#GoNaKleb

Abstract:

Resistance to antibiotics, a serious concern in the field of public health, occurs when a microorganism cannot be controlled or killed by antibiotics. Millions of patients die annually because of Klebsiella Pneumoniae (KP)-caused infectious diseases, a lot of these deaths are the result of organisms that are resistant to antibiotics. The long-term objective of this project is to develop new highly effective and refractory treatment that is highly efficient against KP using specific antibodies conjugated to non-toxic GNPs as NIR responsive photothermal contrast agents. Thus, we plan to obtain a very efficacious pulse laser mode treatment of individual KP agents with minimal effects on the surrounding cells, providing highly localized killing effects for the Ab-GNP targeted bacteria only. In addition, we intend to identify the optimal dose and schedule of administration of this selective nanophotothermal treatment that will cure people with KP infections without causing the emergence of resistance.

NUTRACEUTIC FUNCTIONAL PRODUCT WITH CURATIVE AND PALLIATIVE PROPERTIES OBTAINED FROM ZONAR (LACTOSER) ENRICHED WITH NATURAL BIOACTIVE PRINCIPLES BY USING SOME ECO-INOVATIVE TECHNOLOGIES Call name: P 2 - SP 2.1 - Cecuri de inovare
PN-III-P2-2.1-CI-2017-0632 2017 - 2017

Role in this project: Key expert

Coordinating institution: EMBRYOM CAPITAL INVESTMENT SRL

Project partners: EMBRYOM CAPITAL INVESTMENT SRL (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: http://usamvcluj.ro/eco-zonar/

Abstract:

The work hypothesis of this project is based on the central role of the eco-innovation in the promotion of the industry competitiveness as source of social welfare. Eco-innovation is defined by the European Commission as being «any form of innovation aiming at significant and demonstrable progress towards the goal of sustainable development, by reducing the environmental impact of the economy or achieving a more efficient and responsible use of natural resources». The project ECO-ZONAR aims to contribute, through its specific activities and outcomes, to a better use of resources and to stimulate the competitiveness by using the animal by-products (Whey) in the production of a nutraceutical product with curative and palliative properties, used in various fields of medicine. Through the functional product obtained (Eco-Zonar), the project will contribute to a more efficient and rational use of resources, by converting an animal byproduct into a source of benefits for human health. The ECO-ZONAR will be obtained by using some eco-innovative technologies from whey (Zonar) enriched with bioactive principles extracted from Zingiber officinalis and polyflower honey. The curative and palliative properties of the product will be tested on different in vivo experimental models (detoxifying, antioxidant, hypoglycemic, anti-inflammatory, anti-proliferative) performed on the laboratory rats and mice. The research outcomes will stimulate the exploitation of the green industry, through generating eco-innovation, competitiveness, preservation of the resources, and implicitly will create new jobs. The nutraceutical product developed will be a valuable source of curative and palliative benefits for human health. The necessity identified in EMBRYOM SRL comes from the fact that the Eco-Zonar requires, to be implemented on national/EU market, to performing some rigurous controlled experiments in order to validate the scientific properties of its bioactive principles, respectively their functional synergism on different in vivo models.

The development of dual role silver nanoparticles for the treatment of osteoporosis and bone infections Call name: Projects for Young Research Teams - RUTE -2014 call
PN-II-RU-TE-2014-4-2267 2015 - 2017

Role in this project: Key expert

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/projects.html#NanoAgOst

Abstract:

In 2000, the direct costs related to osteoporotic fractures, in the European Union, exceeded 30 billion euros and they are projected to rise as life expectancy grows.In the field of bone regeneration, the use of growth factors

has been widely researched, but this approach has yet to penetrate into practical applications.The use of small molecules for bone regenerative medicines has been largely overlooked, this approach can minimize or even overcome many of the problems associated with protein-based growth factors.The scientific impact of the proposed research project derives from addressing a still-not achieved and highly addressed aims of alternative antibacterial approaches in bone infections and osteoporosis treatment. The results of the research can open new directions in the fight against antibiotic resistant infections and in the way osteoporosis treatment is addressed. The use of small biological active molecules in conjuncture with antimicrobial metal nanoparticles can open new research directions in the field of nanomedicine, thus highlighting the projects importance. The social impact resides from the need to develop new, targeted therapies in the treatment of osteoporosis and antibiotic resistant bone infections. The proposed functionality approach could lead to a valid prototype for patent application and technological transfer, therefore the proposal has a high economical impact.

Multimodal treatment of pancreatic cancer through phototermic activated plasmonic resonance and selective chemotherapy mediated by silver biocomposites. Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-1553 2014 - 2017

Role in this project:

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); ASOCIATIA AAMIRA APPLIED MATHEMATICS AND INFORMATICS IN RESEARCH AREA JUDETUL CLUJ (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/projects.html#Nanochim

Abstract:

The research aims to explore one of the most modern nano-bio-technological concepts with applications in medicine, vector therapy combined with photo-thermally activated plasmon resonance mechanism. The project aims to use specific peptides and silver biocomposites under chemotherapy treatment in order to obtain selective tissue necrosis and to improve the response to chemotherapy in pancreatic cancer for the first time. The research will be entirely carried out from concept phase to in vitro testing of the suggested method. The project is structured into three consecutive phases, emphasizing the elucidation of all theoretical aspects of the synthesis concerned, and generating multiple solutions for biotreatment of these dual-purpose composites: binding of chemotherapeutic agent and binding of tumor selective agent. The research results in the selection of a synthesis product, followed by drawing up the technical specification required for patenting.

Stem cell therapies for degenerative retinal diseases with the help of nanotechnology Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-1232 2014 - 2017

Role in this project: Partner team leader

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); INSTITUTUL ONCOLOGIC PROF.DR.I.CHIRICUTA CLUJ-NAPOCA (RO); UNIVERSITATEA BABES BOLYAI (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO); CARL ZEISS INSTRUMENTS S.R.L. (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: http://www.granturi.umfcluj.ro/retstem/

Abstract:

The team who elaborated this project proposal has the intention to obtain progress in a field of major importance for the peoples' health and quality of life: the development of a stem cell based therapy, capable to overtake the structure and function of a retina affected by diseases beyond any cure.

The problem to be addressed and solved within this project has an extremely important practical relevance, taking into consideration that its purpose is to find a therapeutic solution for the disabling retinal diseases that affect significantly all the age groups: age related macular degeneration, diabetic retinopathy pigmentary retinopathy, Stargardt disease.

The transplantation of stem cells with the aim to offer neuroprotection and repairment of the injured cells represent new therapeutic strategies.

One end-product of the project is a complex experimental model of retinal reconstruction in which stem cell transplantation is combined with a nanoparticle delivery system for growth factors to improve grafting and differentiation into functional retinal cells. To get a better insight into the pathophysiology of retinal diseases and restoration with stem cells transplantation, the role of animal models is indispensable. In this context, the private company involved in this project, with a recognized tradition in the development of the optical devices, aims to make a technological innovation by developing a portable optical coherence tomograph applicable both to the experimental research (studies on animals) and to the clinical practice (example: the tomographic evaluation of the retina in the prematurely new born infants).

The common denominator in the above-mentioned retinal diseases is the loss of the neural cells (photoreceptors, interneurons, retinal ganglion cells) and of the essential supporting cells (retinal pigmented epithelium). Therefore, the novel therapeutic strategies aim the development of neuroprotective and regenerative strategies. Stem cells have the potential to be used both for neuroprotection and for cell replacement.

The new therapeutic strategies in retinology can be divided into several broad groups: genetic therapy (the augmentation of a gene's function or in the inhibition of a mutated gene), drug therapy ( cromophore supplementation), neuroprotection ( to slow down the degeneration of the photoreceptors with neurotrophic growth factors), electric stimulation of the visual pathways and regenerative medicine.

In recent years, a new field of biotechnology, nanomedicine, makes its way in retinal diseases diagnosis and therapies. The advantages of nanoparticles include delivery of therapeutic agents, targeted delivery of drugs to specific cells or tissue, improved delivery of both water-insoluble drugs and large biomolecule drugs, and reduced side effects.

The general objective of this project is retinal reconstruction with the help of stem cells and functionalized gold nanoparticles with growth factors as local delivery systems.

In parallel we intend to develop some specific objectives: (1) the elaboration of a retinal disease animal model and (2) the elaboration of non-invazive retinal investigation techniques.

This retinal reconstruction model is intended to be as close as possible to the human clinical approaches with the aim to facilitate the translation of the stem cells transplantation into the clinical frame. The delivery of the growth factors with gold nanoparticles in order to improve the implantation and differentiation is a new (original) therapeutic approach in the retinal transplantation.

Within the project structure, the following successive components are individualized: the preparation of the stem cell populations that are going to differentiate into retina specific cells; the creation of the animal model that is going to be used to illustrate the modality in which the stem cells administered by various ways are going to repair a retinal lesion produced by laser photocoagulation;

Photothermal nanotherapeutics for selective eradication of Methicillin- resistant Staphylococcus aureus (MRSA) with biofunctionalized gold nanoparticles. Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1289 2012 - 2016

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO); ASOCIATIA AAMIRA APPLIED MATHEMATICS AND INFORMATICS IN RESEARCH AREA JUDETUL CLUJ (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)

Project website: http://www.nmn.ro/nanostaft.htm

Abstract:

Antibiotic resistance is a growing and increasingly serious public health problem. Infectious diseases caused by MRSA and other bacteria are responsible for millions of deaths each year, and much of this mortality is due to the rise of antibiotic resistant organisms. MRSA has emerged as a major nosocomial pathogen in the last decade. Treatment for MRSA infections is difficult as vancomycin, the only responsive treatment, is partially effective, has considerable toxicity and it is poorly absorbed by body tissues Newer antibiotics may help to offset the onward march of MRSA resistance but new technologies for rapid detection of MRSA carriage and treatment are needed to help reduce the threat in the future. From a clinical perspective, attractive alternative approaches for treating such MRSA resistant strains would be using agents that cause physical damage to the bacteria.

The long term objective of this project is to develop new anti-infectives that are highly effective and refractory to antibiotic resistance exhibited by MRSA using specific antibodies conjugated to gold nanoparticles as NIR responsive photothermal contrast agents. Thus, we plan to obtain a very efficacious pulse laser mode treatment of individual MRSA agents with minimal effects on the surrounding cells, providing highly localized killing effects for the Ab-GnP targeted bacteria only. In addition, we intend to identify the optimal dose and schedule of administration of this selective nanophotothermal treatment that will cure people with MRSA infections without causing the emergence of resistance.

Development and preclinical evaluation of nanoparticulate drug delivery systems for targeted antitumor therapy of colorectal cancer Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1060 2012 - 2016

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); UNIVERSITATEA BABES BOLYAI (RO); BIOTEHNOS SA (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: https://pcca1060.wordpress.com/

Abstract:

The colorectal cancer remains a major health problem being the second cause of death by cancer in the world. Chemotherapy as major therapeutic approach for the treatment of cancer involves a high patient risk because of lack of tumor specificity of the cytotoxic drugs. Moreover the inefficiency and side effects of chemotherapy have been primarily associated with the formulation and biodistribution of the drug, toxicity to normal cells and the acquisition of drug resistance in the cancer cells. In order to overcome chemotherapy drawbacks, therapeutic bionanotechnologies based on the drug targeting concept might be a promise approach for cancer treatment.

Recent studies have shown the active involvement of inflammatory cells infiltrating the tumor, in tumor development by stimulating and supporting tumor angiogenesis. Tumor angiogenesis induced by the inflammatory pathways seems to be a central force in tumor growth and expansion. Inflammatory cell-targeting by using nanoparticulate delivery systems for certain drugs with primary or secondary anti-inflammatory effects in combination with nanoparticulate systems to deliver cytotoxic drugs to tumor cells might be a promise for the antitumor therapy.

Based on this approach, the aim of this proposal is to develop a successfull targeting strategy of two key cell players in tumor development, tumor and inflammatory cells. This aim will be accomplished by two main objectives: to develop suitable nanoparticulate drug delivery systems for selected drugs in the classes mentioned above and to assess their antitumor efficacy. The novelty of the proposal is to use a tumor targeting strategy for both processes vital for tumor progression, tumor cell proliferation and tumor-associated inflammation. Taking into account our premises, development of targeted antitumor nanosystems would have a significant impact on future anticancer therapy.

Nanomediated colon cancer prophylaxis in mice using a MUC-1-conjugated GoldNPs/ dendritic cells synergic vaccine. Call name: Joint Applied Research Projects - PCCA-2011 call, Type 1
PN-II-PT-PCCA-2011-3.1-1586 2012 - 2016

Role in this project: Key expert

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: http://www.nmn.ro/vaccinan.htm

Abstract:

Colon cancer is a major cause of deaths worldwide, and it is expected to rise in the coming years. Importantly, in adults younger than 50 years, CC incidence rates have been increasing by about 1.6% per year since 1998 in men and women. Up to date therapeutic management in colon cancer treatment include surgical resection of the primary tumor, chemotherapeutic agents and radiotherapy. Despite advances in surgical techniques and adjuvant therapy, there has been only a limitted improvement in survival for patients who present advanced neoplasms.

In order to achieve a distinct colon cancer vaccine model, present project aims to develop a new method of immunization through combined administration of functionalized Gold NPs and dendritic stem cells suspensions. The key aim of the project would be to conjugate MUC1 antigen to Gold NPs in order to promote major histocompatibility complex mediated (MHC) antigen presentation by dendrite cells. We hypothesize that the moiety would then contribute to an optimal combined Gold NPs+dendrite cells colon cancer prophylaxy effect. As a result to VACCINAN project, CC patients will have the chance to benefit from improved survival by being offered innovative, improved treatment solutions to be further applied in the near future.

Selective near-infrared plasmonic photothermal terapy (PPTT) of human liver cancer mediated by biofunctionalized gold nanoparticles. Call name: Joint Applied Research Projects - PCCA-2011 call, Type 1
PN-II-PT-PCCA-2011-3.1-1551 2012 - 2016

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR CLUJ-NAPOCA (RO)

Project website: http://nmn.ro/nanoliv.htm

Abstract:

The general goal of this project is to develop a novel therapy for hepatocellular carcinoma (HCC) based on a combination of a treatment strategy that involves gold nanoparticles bound to antibodies and laser irradiation. The strategy involves selective tumor ablation obtained by irradiation of gold nanoparticles that will be targeted to the liver cancer cells by antibodies conjugated to them. Furthermore these nanobiosystems will be tested using in vitro, in vivo and ex vivobiological platforms.

Development of a prophylaxis program for coccidiosis control based on the use of Artemisia annua in chickens Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-0274 2013 - 2016

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA

Project partners: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO); SOCIETATEA NATIONALA "INSTITUTUL PASTEUR" S.A. (RO); STATIUNEA DE CERCETARE - DEZVOLTARE PENTRU CRESTEREA BOVINELOR TARGU MURES (RO); OPREA AVI COM SRL (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)

Project website: http://www.artcoc.ro

Abstract:

Coccidiosis remains one of the most economically important diseases in poultry industry. Control of coccidiosis has focused on prophylaxis with anticoccidial drugs in feed. Their extensive use has inevitably led to the development of drug resistance. The conclusion of the report in 2008 from Commision to the European Parliament was that at the present time, the use of coccidiostats as a preventive measure for the control of coccidiosis is essential, but the Commision stated that the European Commission will continue to monitor the development of new substances and techniques for the prevention. In this context through the proposed project we intend to evaluate the anticoccidial activity of an herbal product, Artemisia annua, as an effort in the development of alternative strategies of coccidiosis control and prevention. Thus, controlled battery experiments, floor pen and field trials will be done during 36 months. All the trials, except the field trial, will be done with single and mixed infections with E acervulina, E tenella and E maxima, Houghton strains.

The safety for the chicken, the activity on the immune system and microbial flora and A annua toxicity will be investigated. One of the partners will crop A annua in order to ensure the product for experiments and for field trial. The expected results of the project is to obtain a natural (herbal) product based on A annua with anti-coccidial activity (patent). Project shows promise in promoting the EU directives of reducing the chemical and pharmaceutical substances. However, its objective EU requirements are fulfilled in the field of food safety making available to poultry farmers a modern alternative for coccidiosis prophylaxis according to European legislation to coccidiostatics. The increase of Romanian researchers international visibility by article publishing and international conferences participations will be one of the desirable, collateral results.

Nanotherapeutics for the selective treatment of pancreatic cancer Call name: Exploratory Research Projects - PCE-2012 call
PN-II-ID-PCE-2012-4-0241 2013 - 2016

Role in this project: Key expert

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR (RO)

Affiliation:

Project website: http://nmn.ro/nanocap.htm

Abstract:

Pancreatic cancer (PC) represents the fourth leading cause of cancer death worldwide.An exciting and new approach to PC treatment is represented by the targeted therapeutics systems.Recent developments in the field of plasmonics offer new opportunities for both primary and multimodal photothermal therapy strategies using nanoparticles.The general goal of this project is to develop a novel nanophotothermolysis system for pancreatic cancer based on a treatment strategy that involves biocompatible laser active nanoparticles bound to novel specific antibodies combined with laser irradiation. We propose an innovative approach for obtaining a high degree of selectivity on pancreatic cancer cells. Furthermore the developed nanobiosystems will be tested using in vitro, in vivo and ex vivo biological platforms.

Development of CA 19-9 plasmid DNA-carbon nanotubes vaccine for pancreatic cancer immunoprophylaxis. Call name: Exploratory Research Projects - PCE-2012 call
PN-II-ID-PCE-2012-4-0243 2013 - 2016

Role in this project: Key expert

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR (RO)

Affiliation: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE - HEPATOLOGIE PROF. DR. OCTAVIAN FODOR (RO)

Project website: http://www.nmn.ro/nanoplasmid.htm

Abstract:

Pancreatic cancer is the most lethal solid tumor in humans. PC is also one of the most intrinsically drug-resistant of all tumors and the lack of effective cytostatics contributes to the increased mortality rates.In patients with cancer, due to the altered expression of proteins involved in antigen processing and presentation, tumor cells are able to avoid recognition by the immune system, and insufficient activation of antitumor immunity leads to poor protective responses. Present proposal aims to genereate a plasmid DNA encoding an immunogenic peptide derived from CA 19-9 antigen an to test it alone or in combination with carbon nanotubes in order to induce eficient anti-tumor immune responses.

LASER mediated photothermal ablation of human pancreatic cancer with immunoconjugated gold nanoparticles. Call name: Projects for Young Research Teams - TE-2011 call
PN-II-RU-TE-2011-3-0251 2011 - 2014

Role in this project: Key expert

Coordinating institution: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE-HEPATOLOGIE PROF. DR. OCTAVIAN FODOR, Departamentul de Nanomedicina

Project partners: INSTITUTUL REGIONAL DE GASTROENTEROLOGIE-HEPATOLOGIE PROF. DR. OCTAVIAN FODOR, Departamentul de Nanomedicina (RO)

Affiliation:

Project website: http://www.nmn.ro/nanopanc.htm

Abstract:

The long term goal of this research project is to develop an efficient treatment of pancreatic carcinoma (PC) for humans based on non-toxic biofunctionalized gold nanoparticles with human serum albumin (HSA) that will enable specific tumor ablation when irradiated by external laser field.

We propose to develop HSA gold conjugated NPs for targeted delivery to pancreatic tumor, using HSA as delivery carrier and Gp60 receptors as therapy target.

The efficacy of the newly developed PCC treatment will be tested by using biological platforms (in vitro-cell lines, in vivo-xenotranplants of human livercancer on mice, ex vivo surgically resected specimens) to optimize and test the NPs. All legal procedures for clinical phase trials will be implemented at this stage.

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects